Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-08-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-0282PMID 28778862PMCID PMC5668148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RUNX transcription factors at the interface of stem cells and cancer.

  2017cited by this paper
• Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

  2016cited by this paper
• CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma

  2016cited by this paper
• Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions

  2015cited by this paper
• Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas

  2015cited by this paper
• Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy

  2015cited by this paper
• Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

  2015cited by this paper
• Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress

  2014cited by this paper
• Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

  2014cited by this paper
• A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.

  2014cited by this paper
• Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy.

  2013cited by this paper
• Eukaryotic ribosome biogenesis at a glance

  2013cited by this paper
• Dysregulation of the basal RNA polymerase transcription apparatus in cancer

  2013cited by this paper
• Old Drug, New Target

  2013cited by this paper
• Dysregulation of RNA polymerase I transcription during disease.

  2013cited by this paper
• Targeting RNA polymerase I transcription and the nucleolus for cancer therapy

  2013cited by this paper
• Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

  2012cited by this paper
• Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

  2012cited by this paper
• Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

  2012cited by this paper
• RNA polymerase I activity is regulated at multiple steps in the transcription cycle: recent insights into factors that influence transcription elongation.

  2012cited by this paper
• Specialized ribosomes: a new frontier in gene regulation and organismal biology

  2012cited by this paper
• Translational medicine: ribosomopathies.

  2011cited by this paper
• Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors.

  2011cited by this paper
• Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

  2011influential reference
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels*

  2010cited by this paper
• Nucleolar organization, growth control and cancer

  2010cited by this paper
• Focus on histone variant H2AX: To be or not to be

  2010cited by this paper
• The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer.

  2010cited by this paper
• Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

  2009cited by this paper
• DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment

  2009cited by this paper
• γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin

  2008cited by this paper
• Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer

  2008cited by this paper
• The DNA damage response pathways: at the crossroad of protein modifications

  2008cited by this paper
• RNA polymerases I and III, non-coding RNAs and cancer.

  2008cited by this paper
• Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

  2008cited by this paper
• H2AX chromatin structures and their response to DNA damage revealed by 4Pi microscopy

  2006cited by this paper
• Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.

  2006cited by this paper
• Nascent pre‐rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma

  2006cited by this paper
• Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy

  2006cited by this paper
• Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.

  2002cited by this paper
• Relapsed ovarian cancer: challenges and management strategies for a chronic disease.

  2002cited by this paper
• Morphological effects of chemotherapy on ovarian carcinoma.

  2002cited by this paper
• ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks*

  2001cited by this paper
• TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line.

  1999cited by this paper
• Cell cycle-dependent regulation of RNA polymerase I transcription: the nucleolar transcription factor UBF is inactive in mitosis and early G1.

  1999cited by this paper
• Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.

  1999cited by this paper
• DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139*

  1998cited by this paper
• p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.

  1996cited by this paper
• Collagenase expression in ovarian cancer cell lines.

  1995cited by this paper
• Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.

  1993cited by this paper
• Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.

  1985cited by this paper
• Comparative properties of five human ovarian adenocarcinoma cell lines.

  1985cited by this paper
• 2. Introduction

  1962cited by this paper
• International Journal of Gynecology and Obstetrics Cancer of the Ovary, Fallopian Tube, and Peritoneum

  year unknowncited by this paper

• DUSP12 regulates NAT10-mediated RNA acetylation to modulate DNA repair and therapeutic response in hepatocellular carcinoma

  2026cites this paper
• The natural alkaloid nitidine chloride targets RNA polymerase I to inhibit ribosome biogenesis and repress cancer cell growth

  2025cites this paper
• NSH76: a selective inhibitor of RRN3 and RNA polymerase I transcription with potential for cancer therapy

  2025cites this paper
• Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain

  2025cites this paper
• A POLR1D-regulating single-nucleotide polymorphism as a predictive marker candidate for platinum-based chemotherapy in gastrointestinal cancers

  2025cites this paper
• The G-quadruplex ligand CX-5461: an innovative candidate for disease treatment

  2025cites this paper
• Ribosome biogenesis and ribosomal proteins in cancer stem cells: a new therapeutic prospect

  2024cites this paper
• LINC01116-dependent upregulation of RNA polymerase I transcription drives oncogenic phenotypes in lung adenocarcinoma

  2024cites this paper
• CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci

  2024cites this paper
• Clinical and translational advances in ovarian cancer therapy

  2023cites this paper
• Fallopian tube lesions as potential precursors of early ovarian cancer: a comprehensive proteomic analysis

  2023cites this paper
• Deregulations of RNA Pol II Subunits in Cancer

  2023cites this paper
• Ribosome-Directed Therapies in Cancer

  2022cites this paper
• A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer

  2022cites this paper
• CMTM6 attenuates cisplatin‐induced cell death in OSCC by regulating AKT/c‐Myc‐driven ribosome biogenesis

  2022cites this paper
• Harnessing preclinical models for the interrogation of ovarian cancer

  2022cites this paper
• Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance

  2022cites this paper
• p53 induces a survival transcriptional response after nucleolar stress

  2021cites this paper
• HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN

  2021cites this paper
• Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling

  2021cites this paper
• Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461

  2021cites this paper
• Preneoplastic Lesions Fimbria Early Diagnosis Markers Underlying Timeline Mechanisms at The Origin of Ovarian Cancer in BRAC1/2 Patients: Case Reports Based on Proteogenomic Study

  2021cites this paper
• CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition

  2021cites this paper
• Harnessing the Nucleolar DNA Damage Response in Cancer Therapy

  2021cites this paper
• Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

  2021cites this paper
• CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

  2021cites this paper
• HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN

  2021cites this paper
• Role of Cervical Cancer Radiotherapy in the Expression of EGFR and p53 Gene

  2020cites this paper
• CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

  2020cites this paper
• Preneoplastic lesions fimbria pan-proteomic studies establish the fimbriectomy benefit for BRCA1/2 patients and identify early diagnosis markers of HGSC

  2020cites this paper
• The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability

  2020cites this paper
• Molecular Dynamics Study on the Binding of an Anticancer DNA G-Quadruplex Stabilizer, CX-5461, to Human Telomeric, c-KIT1, and c-Myc G-Quadruplexes and a DNA Duplex

  2020cites this paper
• The Application of Patient-Derived Xenograft Models in Gynecologic Cancers

  2020cites this paper
• Dynamic analysis of N-glycomic and transcriptomic changes in the development of ovarian cancer cell line A2780 to its three cisplatin-resistant variants

  2020cites this paper
• Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age

  2020cites this paper
• Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells

  2019cites this paper
• Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

  2019cites this paper
• Biomarkers of drug resistance in ovarian cancer – an update

  2019cites this paper
• POLR1B is upregulated and promotes cell proliferation in non-small cell lung cancer

  2019cites this paper
• CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage

  2019cites this paper
• Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics

  2019cites this paper
• The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers

  2019cites this paper
• A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity

  2019cites this paper
• Discovery of novel inhibitors of ribosome biogenesis by innovative high throughput screening strategies.

  2019cites this paper
• Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance.

  2019cites this paper
• The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity

  2019cites this paper
• Nucleolar targeting in combination with radiation for cancer therapy.

  2019cites this paper
• Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy

  2018cites this paper
• Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer

  2017cites this paper